Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Multiple sclerosis and covid-19

Published on: 08/07/2020 Reading time: 1 min
Sclérose en plaques et COVID-19

DOES MULTIPLE SCLEROSIS (MS) ALTER THE RISK OF DEVELOPING A SEVERE FORM OF COVID-19 INFECTION? WHAT ARE THE CLINICAL FEATURES AND EFFECTS OF CORONAVIRUS INFECTION IN PATIENTS WITH MS? DO SPECIFIC TREATMENTS FOR SEPSIS INCREASE OR DECREASE THE SEVERITY OF THE VIRAL INFECTION?

At the Paris Brain Institute, a study coordinated by Dr Céline LOUAPRE, neurologist (AP-HP.Sorbonne University), referent doctor of the Clinical Investigation Centre (CIC) and researcher in the team of Profs LUBETZKI and STANKOFF has made it possible to answer these questions.

The COVISEP register is based on a cohort of patients from all the expert centres and neurologists who follow MS patients in France. The retrospective and observational study, coordinated by Dr LOUAPRE, which was published in the scientific journal JAMA Neurology, involved 347 multiple sclerosis patients infected with COVID-19 between 1 March and 21 May 2020.

The severity of COVID-19 was assessed on a scale ranging from 1 (no hospitalisation, no activity limitation) to 7 (death).

Of the 347 patients included in the study, 284 were receiving immunomodulatory or immunosuppressive therapy for their MS. The rate of patients hospitalised due to COVID-19 was 21%, and the rate of COVID-19-related deaths was 3.5%, slightly higher than expected for a population with an average age of 44 years.

The results of this study show that the risk factors for COVID-19 severity (requiring at least hospitalisation) are EDSS score (a scale reflecting the severity of neurological disability), age and obesity. In contrast, immunomodulatory or immunosuppressive treatments were not associated with an increase in the severity of COVID-19.

These results now make it possible to better adapt the clinical management of multiple sclerosis patients presenting one of the risk factors identified in the case of COVID-19 contamination.

Sources

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis  Céline LOUAPRE  et al.
PMID: 32589189  DOI: 10.1001/jamaneurol.2020.2581

Our news on the subject

Le développement du cerveau a une part d’aléatoire
The stochastic aspect of brain development
Although every person’s personality is the result of genetic and environmental factors, these are not the only factors at play. Bassem Hassan and his team at Paris Brain Institute have discovered that, in fruit flies (drosophila), individuality also...
05.12.2025 Research, science & health
Analyse MERSCOPE
New treatment pathways for brain malformation-linked focal epilepsy?
A study by Stéphanie Baulac’s team has revealed somatic mutations in different cell types in patients with type 2 focal cortical dysplasia. This disease causes drug-resistant epileptic seizures, for which the main treatment option is currently...
05.12.2025 Research, science & health
Un iceberg
The ICEBERG cohort, 10 years of collective scientific and medical mobilization
The ICEBERG cohort, initiated 10 years ago, is interested in studying factors predictive of the onset and progression of Parkinson’s disease.
05.15.2025 Research, science & health
La huntingtine est une protéine indispensable au développement embryonnaire, à la formation et au maintien du tissu cérébral.
Huntington's Disease: The Energy Hypothesis Gets Traction
Huntington's disease, a rare hereditary neurological disorder, is associated with an energy deficit that precedes the onset of symptoms and is closely linked to their progression. At Paris Brain Institute, Fanny Mochel and her colleagues are testing...
02.11.2025 Research, science & health
À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Monocyte – un globule blanc qui se différencie en macrophage. Crédit : Université d’Edinbourg.
Discovery of a Macrophage Anomaly in Multiple Sclerosis
Certain patients with multiple sclerosis (MS) can partially regenerate myelin—the protective sheath that surrounds nerve fibers—which is damaged during the evolution of the disease. In studying how immune cells influence this remyelination...
12.19.2024 Research, science & health
See all our news